Clinical Trials Currently Recruiting Participants

For more information please visit clinicaltrials.gov

An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer (BOLERO 4)

  • Sponsor: Novartis Pharmaceuticals
  • ClinicalTrials.gov Identifier: NCT01698918

A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCAAssociated Breast Cancer (BROCADE 3)

  • Sponsor: AbbVie
  • ClinicalTrials.gov Identifier: NCT02163694

A Registry of Caris Life Sciences® Molecular Intelligence™ Service (Biomarker Assessment Results) Intended for Correlation with Cancer Clinical Outcomes

  • Sponsor: Caris Science, Inc.
  • ClinicalTrials.gov Identifier: NCT02678754

Cryoablation of Low Risk Breast Cancer Less Than 1.5 cm: An Evaluation of Local Recurrence (ICE3)

  • Sponsor: IceCure Medical Ltd.
  • ClinicalTrials.gov Identifier: NCT02200705

A Study of Atezolizumab in Combination with Nab-Paclitaxel Compared With Placebo with Nab-Paclitaxel for Participants with Previously Untreated Metastatic Triple-Negative Breast Cancer (IMPASSION)

  • Sponsor: Hoffman-LaRoche
  • ClinicalTrials.gov Identifier: NCT02425891

A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy (KATE2)

  • Sponsor: Hoffman-LaRoche
  • ClinicalTrials.gov Identifier: NCT02924883

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NER1301)

  • Sponsor: Puma Biotechnology, Inc.
  • ClinicalTrials.gov Identifier: NCT01808573

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)

  • Sponsor: Hoffman-LaRoche
  • ClinicalTrials.gov Identifier: NCT02340221

Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System

  • Sponsor: XOFT, Inc.
  • Collaborator: Icad, Inc.
  • ClinicalTrials.gov Identifier: NCT01644669

Clinical Studies that are On-going, not Recruiting Participants

For more information please visit clinicaltrials.gov

Prospective Neo-adjuvant REGISTRY Trial Linking MammaPrint, Subtyping and Treatment Response: Neoadjuvant Breast Registry - Symphony Trial (NBRST)

  • Sponsor: Agendia
  • ClinicalTrials.gov Identifier: NCT01479101

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery (B-40)

  • Sponsor: NSABP Foundation, Inc.
  • Collaborator: National Cancer Institute
  • ClinicalTrials.gov Identifier: NCT00408408

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer (B-41)

  • Sponsor: NSABP Foundation, Inc.
  • Collaborator: GlaxoSmithKline
  • ClinicalTrials.gov Identifier: NCT00486668

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer (B-42)

  • Sponsor: NSABP Foundation, Inc.
  • Collaborator: National Cancer Institute
  • ClinicalTrials.gov Identifier: NCT00382070

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy (B-43)

  • Sponsor: NSABP Foundation, Inc.
  • Collaborator: National Cancer Institute
  • ClinicalTrials.gov Identifier: NCT00769379

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (PUMA 3004)

  • Sponsor: Puma Biotechnology, Inc.
  • ClinicalTrials.gov Identifier: NCT00878709

Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. (SWOG SO307)

  • Sponsor: Southwest Oncology Group
  • Collaborators: National Cancer Institute
  • North Central Cancer Treatment Group
  • Eastern NSABP Foundation
  • Cancer & Leukemia Group
  • NCIC Clinical Trials Group
  • ClinicalTrials.gov Identifier: NCT00127205

Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases (SWOG SO702)

  • Sponsor: Southwest Oncology Group
  • Collaborators: National Cancer institute
  • Novartis Pharmaceuticals
  • ClinicalTrials.gov Identifier: NCT00874211

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

  • Sponsor: Hoffman-LaRoche
  • Collaborators: NSABP Foundation
  • German Breast Group
  • ClinicalTrials.gov Identifier: NCT01772472

The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients. (CARIS BIOREPOSITORY)

  • Sponsor: Caris Science, Inc.
  • ClinicalTrials.gov Identifier: NCT01499394